Form 4: USANA Health Sciences: Chief Legal Officer Joshua Foukas Reports Stock Transactions

Joshua Foukas, Chief Legal Officer of USANA Health Sciences, reports transactions involving restricted stock units and common stock.

Summary

• On February 6th and 7th, 2025, Joshua Foukas, the Chief Legal Officer of USANA Health Sciences, engaged in transactions involving restricted stock units and common stock.
• On February 6th, 2025, 3,110 restricted stock units vested and were converted into common stock, and 1,318 shares were disposed of at a price of $31.21.
• Following these transactions on February 6th, Foukas directly owns 1,792 shares of common stock and 25,416 restricted stock units.
• On February 7th, 2025, 1,572 restricted stock units vested and were converted into common stock, and 666 shares were disposed of at a price of $30.65.
• Following these transactions on February 7th, Foukas directly owns 2,698 shares of common stock and 23,844 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a neutral report of stock transactions, with no inherent positive or negative sentiment.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, which is common in publicly traded companies. It provides transparency into the trading activities of key personnel.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency in insider trading.
• Similar filings are made by officers and directors of companies like Herbalife Nutrition and Nu Skin Enterprises, which operate in the same industry as USANA Health Sciences.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely minimal.

Key Dates

Keywords

USANA Health Sciences, Joshua Foukas, Chief Legal Officer, Form 4, Stock Transactions, Restricted Stock Units, Common Stock, Beneficial Ownership